# US 2026/0091109 A1 · Method for Treating Alzheimer's Disease

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2026/0091109 A1
- Document ID: US20260091109A1
- Status: Published application
- Kind: A1
- Application number: 19/239,695
- Filed: 2025-06-16
- Published: 2026-04-02
- Earliest claimed: 2014-12-02
- Assignees: Biogen International Neuroscience GmbH
- Applicants: Biogen International Neuroscience GmbH
- Inventors: James L. Ferrero; Leslie Lugene Williams; Jeffrey Joseph Sevigny
- Web page: https://patentgrep.com/patent/US20260091109A1

## CPC

- A61K 39/3955: {against proteinaceous materials, e.g. enzymes, hormones, lymphokines}
- A61P 25/28: for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
- C07K 16/18: against material from animals or humans
- C07K 16/28: against receptors, cell surface antigens or cell surface determinants
- A61K 2039/505: {comprising antibodies}
- A61K 2039/545: {characterised by the dose, timing or administration schedule}
- C07K 2317/21: from primates, e.g. man
- A61K: PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES (devices or methods specially adapted for bringing pharmaceutical products into particular physical or administering forms A61J3/00; chemical aspects of, or use of materials for deodorisation of air, for disinfection or sterilisation, or for bandages, dressings, absorbent pads or surgical articles A61L; soap compositions C11D)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- C07K: PEPTIDES (peptides in foodstuffs A23; obtaining protein compositions for foodstuffs, working-up proteins for foodstuffs A23J; preparations for medicinal purposes A61K; peptides containing beta-lactam rings C07D; cyclic dipeptides not having in their molecule any other peptide link than those which form their ring, e.g. piperazine-2,5-diones, C07D; ergot alkaloids of the cyclic peptide type C07D519/02; macromolecular compounds having statistically distributed amino acid units in their molecules, i.e. when the preparation does not provide for a specific; but for a random sequence of the amino acid units, homopolyamides and block copolyamides derived from amino acids C08G69/00; macromolecular products derived from proteins C08H1/00; preparation of glue or gelatine C09H; single cell proteins, enzymes C12N; genetic engineering processes for obtaining peptides C12N15/00; compositions for measuring or testing processes involving enzymes C12Q; investigation or analysis of biological material G01N33/00)

## Abstract

A method for treatment of a human patient for Alzheimer's disease (AD) comprises sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody to the patient. In preferred embodiments, the antibody is administered in increasing amounts over a period of time. In preferred embodiments, the susceptibility of the patient to amyloid related imaging abnormalities (ARIA) is thereby reduced.

## Claims

### Claim 1

A method for treatment of a human patient for Alzheimer's disease (AD), comprising:
sequentially administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody in increasing amounts over a period of time to the patient, wherein, multiple doses of 1 mg/kg, 3 mg/kg, 6 mg/kg, and/or 10 mg/kg of body weight of the patient are administered to the patient at periodic intervals, optionally wherein the periodic intervals are about 4 weeks, optionally wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and
(1) the VH comprises a first complementarity determining region (VHCDR1) with the amino acid sequence of SEQ ID NO:3, a VHCDR2 with the amino acid sequence of SEQ ID NO:4, and a VHCDR3 with the amino acid sequences of SEQ ID NO:5, and the VL comprises a VLCDR1 with the amino acid sequence of SEQ ID NO:6, a VLCDR2 with the amino acid sequence of SEQ ID NO:7, and a VLCDR3 with the amino acid sequence of SEQ ID NO:8, and
(2) the antibody further comprises a human IgG1 constant region,
further optionally wherein the antibody comprises the VH comprising the amino acid sequence of SEQ ID NO:1 and the VL comprising the amino acid sequence of SEQ ID NO:2.

### Claim at position 2

-5. (canceled)

### Claim 6 (depends on 1)

The method of claim 1, wherein,
1-5 doses of 1 mg/kg of body weight of the patient are administered to the patient;
1-5 doses of 3 mg/kg of body weight of the patient are administered to the patient; and
doses of 6 mg/kg of body weight of the patient are administered to the patient until the termination of treatment.

### Claim at position 4

-10. (canceled)

### Claim 11 (depends on 1)

The method of claim 1, comprising:
(A) administering the monoclonal antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(B) 4 weeks after step (A), administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(C) 4 weeks after step (B), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(D) 4 weeks after step (C), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(E) 4 weeks after step (D), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(F) 4 weeks after step (E), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(G) 4 weeks after step (F), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient; and
(H) in consecutive intervals of 4 weeks after step (G), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient;
wherein 14 doses are administered about 4 weeks apart over about 52 weeks;
to thereby reduce the susceptibility of the patient to amyloid related imaging abnormalities (ARIA).

### Claim at position 6

-15. (canceled)

### Claim 16 (depends on 11)

The method of claim 11, wherein the administration is performed intravenously.

### Claim at position 8

-18. (canceled)

### Claim 19 (depends on 1)

The method of claim 1, wherein:
(1) a fixed dose of
3 mg/kg of body weight is administered to the patient every 4 weeks; or
6 mg/kg of body weight is administered to the patient every 4 weeks: or
(2) the patient is an ApoE4 carrier and
a fixed dose of 6 mg/kg of body weight is administered to the patient every 4 weeks; or
a fixed dose of 10 mg/kg of body weight is administered to the patient every 4 weeks.

### Claim at position 10

-22. (canceled)

### Claim 23 (depends on 1)

The method of claim 1, wherein:
(1) the patient is an ApoE4 carrier or and ApoE4 non-carrier and the method comprises:
(A) administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(B) 4 weeks after step (A), administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(C) 4 weeks after step (B), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(D) 4 weeks after step (C), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(E) 4 weeks after step (D), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(F) 4 weeks after step (E), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(G) 4 weeks after step (F), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient; and
(H) in consecutive intervals of 4 weeks after step (G), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient for an indefinite period of time,
(2) the patient is an ApoE4 non-carrier and the method comprises:
(A) administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(B) 4 weeks after step (A), administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(C) 4 weeks after step (B), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient:
(D) 4 weeks after step (C), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient;
(E) 4 weeks after step (F), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient; and
(F) 4 weeks after step (F), administering the antibody to the patient in an amount of 6 mg/kg of body weight of the patient; and
(G) in consecutive intervals of 4 weeks after step (F), administering the antibody to the patient in an amount of 10 mg/kg of body weight of the patient for an indefinite period of time: or
(3) the patient is an ApoE4 carrier and the method comprises:
(A) administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient;
(B) 4 weeks after step (A), administering the antibody to the patient in an amount of 1 mg/kg of body weight of the patient; and
(C) in consecutive intervals of 4 weeks after step (B), administering the antibody to the patient in an amount of 3 mg/kg of body weight of the patient.

### Claim at position 12

-27. (canceled)

### Claim 28

A method for treatment of a human patient for Alzheimer's disease (AD), comprising:
administering multiple doses of a recombinant, fully human, anti-amyloid beta monoclonal antibody over a period of time to the patient,
wherein the patient is
(a) n ApoE4 carrier and the monoclonal antibody is administered in an effective amount of 1 mg/kg or 3 mg/kg of the patient's body weight; or
(b) an ApoE4 non-carrier and the antibody is administered in an effective amount of 3 mg/kg or 6 mg/kg or 10 mg/kg of the patient's body weight,
optionally wherein the antibody comprises a heavy chain variable region (VH) and a light chain variable region (VL), and
(1) the VH comprises a first complementarity determining region (VHCDR1) with the amino acid sequence SEQ ID NO:3, a VHCDR2 with the amino acid sequence SEQ ID NO:4, and a VHCDR3 with the amino acid sequences SEQ ID NO:5, and the VL comprises a VLCDR1 with the amino acid sequence SEQ ID NO:6, a VLCDR2 with the amino acid sequence SEQ ID NO:7, and a VLCDR3 with the amino acid sequence SEQ ID NO:8, and
(2) the antibody further comprises a human IgG1 constant region,
further optionally wherein the antibody comprises the VH comprising the amino acid sequence of SEQ ID NO:1 and the VL comprising the amino acid sequence of SEQ ID NO:2.

### Claim at position 14

-31. (canceled)

### Claim 32 (depends on 1)

The method of claim 1, comprising:
(A) administering a first dose of the antibody to the patient in an amount of 1 mg/kg of body weight of the patient, followed by a second dose in an amount of 1 mg/kg of body weight four weeks after the first dose;
(B) in four week intervals after the second dose, administering doses 3, 4, 5, and 6 of the antibody to the patient in an amount of 3 mg/kg of body weight; and
(C) in four week intervals after administration of dose 6, administering doses 7 and 8 of the antibody to the patient in an amount of 6 mg/kg of body weight: optionally wherein the method further comprises:
(D) in four week intervals after dose 8, administering doses 9-14 of the antibody to the patient in an amount of 6 mg/kg of body weight: or
in four week intervals after dose 8, administering doses 9-20 of the antibody to the patient in an amount of 6 mg/kg of body weight.

### Claim at position 16

-34. (canceled)

### Claim 35 (depends on 32)

The method of claim 32, wherein:
(1) 12 weeks after the last dose of antibody at 6 mg/kg of body weight, administering the antibody to the patient in an amount of 3 mg/kg in consecutive 12 week intervals; or
four weeks after the last dose of antibody at 6 mg/kg of body weight, administering the antibody to the patient in an amount of 1 mg/kg body weight in consecutive four-week intervals.

### Claim at position 18

-37. (canceled)

### Claim 38 (depends on 1)

The method of claim 1, comprising:
(A) administering a first dose of the antibody to the patient in an amount of 1 mg antibody/kg of body weight of the patient, followed by a second dose in an amount of 1 mg/kg of body weight four weeks after the first dose;
(B) in four week intervals after the second dose, administering doses 3 and 4 to the patient in an amount of 3 mg of antibody/kg of body weight; and
(C) in four week intervals after administration of dose 4, administering doses 5 and 6 of the antibody to the patient in an amount of 6 mg/kg of body weight; and.
(D) four weeks after administration of dose 6, administering dose 7 of the antibody to the patient in an amount of 10 mg/kg of body weight: optionally wherein the method further comprises:
(E) in four week intervals after dose 7, administering doses 8-14 of the antibody to the patient in an amount of 10 mg/kg of body weight: or
in four week intervals after dose 7, administering doses 8-20 of the antibody to the patient in an amount of 10 mg/kg of body weight.

### Claim at position 20

-40. (canceled)

### Claim 41 (depends on 38)

The method of claim 38, wherein 12 weeks after the last dose of antibody at 10 mg/kg of body weight, administering the antibody to the patient in an amount of 3 mg/kg in consecutive 12 week intervals.

### Claim 42 (depends on 38)

The method of claim 38, wherein four weeks after the last dose of antibody at 10 mg/kg of body weight, administering the antibody to the patient in an amount of 1 mg/kg body weight in consecutive four week intervals.

### Claim 43

(canceled)

### Claim 44 (depends on 1)

The method of claim 1, comprising:
(A) administering a first dose of the antibody to the patient in an amount of 1 mg antibody/kg of body weight of the patient;
(B) four weeks after the first dose, administering a second dose of the antibody to the patient in an amount of 1 mg/kg of body weight; and
(C) four weeks after the second dose, administering dose 3 of the antibody to the patient in an amount of 3 mg/kg of body weight.

### Claim 45 (depends on 44)

The method of claim 44, further comprising
(D) in four week intervals after dose 3, administering doses 4-14 of the antibody to the patient in an amount of 3 mg/kg of body weight or
in four week intervals after dose 3, administering doses 4-20 of the antibody to the patient in an amount of 3 mg/kg of body weight.

### Claim at position 26

-49. (canceled)

### Claim 50 (depends on 1)

The method of claim 1, comprising:
(A) administering a first dose of the antibody to the patient in an amount of 1 mg antibody/kg of body weight of the patient, followed by a second dose in an amount of 1 mg/kg of body weight four weeks after the first dose;
(B) in four week intervals after the second dose, administering doses 3 and 4 to the patient in an amount of 3 mg/kg of body weight; and
(C) four weeks after dose 4, administering dose 5 of the antibody to the patient in an amount of 6 mg/kg of body weight.

### Claim 51 (depends on 50)

The method of claim 50, further comprising
(D) in four week intervals after dose 5, administering doses 6-14 of the antibody to the patient in an amount of 6 mg/kg of body weight; or
in four week intervals after dose 5, administering doses 6-20 of the antibody to the patient in an amount of 6 mg/kg of body weight.

### Claim 52

(canceled)

### Claim 53 (depends on 50)

The method of claim 50, wherein 12 weeks after the last dose of antibody at 6 mg/kg of body weight, administering the antibody to the patient in an amount of 3 mg/kg in consecutive intervals of 12 weeks.

### Claim 54 (depends on 50)

The method of claim 50, wherein four weeks after the last dose of antibody at 6 mg/kg of body weight, administering the antibody to the patient in an amount of 1 mg/kg in consecutive intervals of 4 weeks.

### Claim 55

(canceled)

### Claim 56 (depends on 1)

The method of claim 1, comprising:
(A) administering a first dose of the antibody to the patient in an amount of 1 mg/kg of body weight of the patient, followed by a second dose in an amount of 1 mg/kg of body weight four weeks after the first dose;
(B) in four week intervals after the second dose, administering doses 3, 4, 5, and 6 of the antibody to the patient in an amount of 3 mg/kg of body weight; and
(C) in four week intervals after administration of dose 6, administering doses 7, 8, 9, 10, and 11 of the antibody to the patient in an amount of 6 mg/kg of body weight;
and.
(D) four weeks after administration of dose 11, administering dose 12 of the antibody to the patient in an amount of 10 mg/kg of body weight.

### Claim 57 (depends on 56)

The method of claim 56, further comprising
(E) in four week intervals after dose 12, administering dose 13 and dose 14 of the antibody to the patient in an amount of 10 mg/kg of body weight; or
in four week intervals after dose 12, administering doses 13-20 of the antibody to
the patient in an amount of 10 mg/kg of body weight.

### Claim at position 35

-68. (canceled)
